首页 | 本学科首页   官方微博 | 高级检索  
     


Recombinant activated factor VII for intractable bleeding post splenectomy in a patient with myeloproliferative disorder.
Authors:Abdul Rahman D El Kinge  Rami A Mahfouz  Ali I Shamseddine  Ali T Taher
Affiliation:Division of Hematology/Oncology, American University of Beirut Medical Center, Beirut, Lebanon.
Abstract:Recombinant activated factor VII has been Food and Drug Administration approved to treat hemorrhages in hemophiliac patients with inhibitors and in acquired hemophilia patients. Recombinant activated factor VII use has also been considered for the management of uncontrolled bleeding in a number of congenital and acquired hemostatic abnormalities. The myeloproliferative disorders are a group of clonal hematologic diseases where, frequently, abnormal platelet function is considered a hallmark. This is the first case report addressing the clinical benefit of off-label use of recombinant activated factor VII in an attempt to control intractable bleeding in a patient with a myeloproliferative disorder after splenectomy.
Keywords:
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号